PRISM BioLab Co.,LTD (TYO:206A)
85.00
+1.00 (1.19%)
Nov 18, 2026, 10:48 AM JST
PRISM BioLab Co.,LTD Revenue
In the fiscal year ending September 30, 2026, PRISM BioLab Co.,LTD had annual revenue of 518.00M JPY, down -23.52%. PRISM BioLab Co.,LTD had revenue of 148.32M in the quarter ending September 30, 2026, a decrease of -59.73%. That makes PRISM BioLab Co.,LTD the 41,284th largest company in the world by revenue and 3,836th in Japan.
Revenue
518.00M
Revenue Growth
-23.52%
P/S Ratio
6.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.14B
Revenue by Geography
- United States of America 523.50M 77.3%
- Japan 110.00M 16.2%
- Switzerland 43.83M 6.5%
Fiscal year ended Sep 30, 2025 See the full PRISM BioLab Co.,LTD breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2026 | 518.00M | -159.33M | -23.52% |
| Sep 30, 2025 | 677.33M | 371.71M | 121.62% |
| Sep 30, 2024 | 305.62M | 192.69M | 170.64% |
| Sep 30, 2023 | 112.93M | -441.07M | -79.62% |
| Sep 30, 2022 | 554.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| MEDINET | 998.00M |
| SUSMED,Inc. | 679.00M |
| Kringle Pharma | 442.00M |
| D. Western Therapeutics Institute | 140.90M |
| Ribomic | 19.00M |